Immunic, Inc.

DB:10VA Stock Report

Market Cap: €96.7m

Immunic Past Earnings Performance

Past criteria checks 0/6

Immunic's earnings have been declining at an average annual rate of -21.8%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-21.8%

Earnings growth rate

17.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-235.1%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Immunic makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:10VA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-971878
30 Jun 240-951876
31 Mar 240-981779
31 Dec 230-941683
30 Sep 230-1291685
30 Jun 230-1271581
31 Mar 230-1251677
31 Dec 220-1201571
30 Sep 220-851569
30 Jun 220-831468
31 Mar 220-791467
31 Dec 210-931361
30 Sep 210-831354
30 Jun 210-771349
31 Mar 210-701144
31 Dec 200-441039
30 Sep 200-411833
30 Jun 200-361830
31 Mar 200-391626
31 Dec 190-351523
30 Sep 190-32521
30 Jun 190-26315
31 Mar 190-14311
31 Dec 180-12210
30 Sep 180-1029
31 Dec 170-1019
31 Dec 160-111

Quality Earnings: 10VA is currently unprofitable.

Growing Profit Margin: 10VA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 10VA is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.

Accelerating Growth: Unable to compare 10VA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 10VA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 10VA has a negative Return on Equity (-235.1%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:41
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunic, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets